PUBLISHER: QYResearch | PRODUCT CODE: 1867581
PUBLISHER: QYResearch | PRODUCT CODE: 1867581
Peptide Cancer Vaccine - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Peptide Cancer Vaccine was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of 19.8% during the forecast period 2025-2031.
Peptide cancer vaccines are innovative immunotherapy products designed based on specific tumor-associated antigen peptides. By delivering selected peptide sequences into patients, these vaccines activate T cells within the immune system to recognize and attack tumor cells, achieving targeted anti-cancer effects. Compared to traditional therapies, peptide vaccines offer strong specificity, low side effects, and ease of production, and can be combined with other immunotherapies or chemotherapies to enhance treatment efficacy. With advancements in molecular biology and immunology, peptide cancer vaccines demonstrate broad potential in personalized treatments and applications across multiple tumor types, marking a significant breakthrough and emerging trend in the field of tumor immunotherapy.
The global increase in cancer patient populations drives strong demand for effective, safe, and personalized treatment solutions. Annual reports from leading biopharmaceutical companies highlight intensified investments in peptide cancer vaccine R&D, fostering technological innovation and clinical trial progress to strengthen market competitiveness. Governments worldwide support innovative medical technologies through policies and funding, accelerating peptide vaccine development and commercialization. The strong specificity and combinational therapy potential of peptide vaccines meet diverse needs across cancer types and patient populations, especially demonstrating value in refractory and recurrent tumors. The widespread adoption of precision medicine concepts and advances in bioinformatics-aided design further enhance R&D efficiency and market penetration.
The peptide cancer vaccine market faces challenges including high technical complexity, lengthy development cycles, and stringent clinical validation requirements. Regulatory policies and approval processes vary across countries and regions, increasing difficulty and cost for international market expansion. Market competition intensifies amid coexistence of traditional therapies and multiple emerging immunotherapies, requiring continuous innovation to maintain leadership. High R&D investment and production costs limit participation of some small and medium enterprises and broader product accessibility. Uncertainties in efficacy and safety necessitate strengthened clinical data support and risk management to ensure market acceptance and long-term competitiveness.
Future downstream demand for peptide cancer vaccines will exhibit personalization, diversification, and integration. Major comprehensive hospitals and oncology centers serve as primary markets, emphasizing treatment efficacy, safety, and synergy with existing therapies. Patient demand for precise and low-side-effect innovative treatments fuels rapid growth in personalized peptide vaccine customization and combination therapies. Advances in companion diagnostics and biomarkers enable more precise patient matching, maximizing therapeutic outcomes. Suppliers must continually enhance R&D capabilities and service quality to meet complex and evolving clinical needs and regulatory environments.
This report aims to provide a comprehensive presentation of the global market for Peptide Cancer Vaccine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Peptide Cancer Vaccine by region & country, by Pipeline, and by Application.
The Peptide Cancer Vaccine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Peptide Cancer Vaccine.
Market Segmentation
By Company
- Boston Biomedical
- Ultimovacs
- BrightPath Biotherapeutics
- TapImmune
- Immatics
- Sellas
- Imugene
- VAXON Biotech
- Generex Biotechnology
- ISA Pharmaceuticals
- OncoTherapy Science
Segment by Pipeline
- ITK-1
- GRN-1201
- TPIV200
- TPIV110
- UV1
- Galinpepimut-S
- TARP 27-35
- HER-Vaxx
- Vx-001
- Others
Segment by Application
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Peptide Cancer Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Pipeline, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Peptide Cancer Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Peptide Cancer Vaccine in country level. It provides sigmate data by Pipeline, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Peptide Cancer Vaccine Product Introduction
- 1.2 Global Peptide Cancer Vaccine Market Size Forecast (2020-2031)
- 1.3 Peptide Cancer Vaccine Market Trends & Drivers
- 1.3.1 Peptide Cancer Vaccine Industry Trends
- 1.3.2 Peptide Cancer Vaccine Market Drivers & Opportunity
- 1.3.3 Peptide Cancer Vaccine Market Challenges
- 1.3.4 Peptide Cancer Vaccine Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Peptide Cancer Vaccine Players Revenue Ranking (2024)
- 2.2 Global Peptide Cancer Vaccine Revenue by Company (2020-2025)
- 2.3 Key Companies Peptide Cancer Vaccine Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Peptide Cancer Vaccine Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Peptide Cancer Vaccine
- 2.6 Peptide Cancer Vaccine Market Competitive Analysis
- 2.6.1 Peptide Cancer Vaccine Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Peptide Cancer Vaccine Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Pipeline
- 3.1 Introduction by Pipeline
- 3.1.1 ITK-1
- 3.1.2 GRN-1201
- 3.1.3 TPIV200
- 3.1.4 TPIV110
- 3.1.5 UV1
- 3.1.6 Galinpepimut-S
- 3.1.7 TARP 27-35
- 3.1.8 HER-Vaxx
- 3.1.9 Vx-001
- 3.2 Global Peptide Cancer Vaccine Sales Value by Pipeline
- 3.2.1 Global Peptide Cancer Vaccine Sales Value by Pipeline (2020 VS 2024 VS 2031)
- 3.2.2 Global Peptide Cancer Vaccine Sales Value, by Pipeline (2020-2031)
- 3.2.3 Global Peptide Cancer Vaccine Sales Value, by Pipeline (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Breast Cancer
- 4.1.2 Lung Cancer
- 4.1.3 Melanoma
- 4.1.4 Prostate Cancer
- 4.1.5 Others
- 4.2 Global Peptide Cancer Vaccine Sales Value by Application
- 4.2.1 Global Peptide Cancer Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Peptide Cancer Vaccine Sales Value, by Application (2020-2031)
- 4.2.3 Global Peptide Cancer Vaccine Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Peptide Cancer Vaccine Sales Value by Region
- 5.1.1 Global Peptide Cancer Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Peptide Cancer Vaccine Sales Value by Region (2020-2025)
- 5.1.3 Global Peptide Cancer Vaccine Sales Value by Region (2026-2031)
- 5.1.4 Global Peptide Cancer Vaccine Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Peptide Cancer Vaccine Sales Value, 2020-2031
- 5.2.2 North America Peptide Cancer Vaccine Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Peptide Cancer Vaccine Sales Value, 2020-2031
- 5.3.2 Europe Peptide Cancer Vaccine Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Peptide Cancer Vaccine Sales Value, 2020-2031
- 5.4.2 Asia Pacific Peptide Cancer Vaccine Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Peptide Cancer Vaccine Sales Value, 2020-2031
- 5.5.2 South America Peptide Cancer Vaccine Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Peptide Cancer Vaccine Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Peptide Cancer Vaccine Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Peptide Cancer Vaccine Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Peptide Cancer Vaccine Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Peptide Cancer Vaccine Sales Value, 2020-2031
- 6.3.2 United States Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- 6.3.3 United States Peptide Cancer Vaccine Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Peptide Cancer Vaccine Sales Value, 2020-2031
- 6.4.2 Europe Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- 6.4.3 Europe Peptide Cancer Vaccine Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Peptide Cancer Vaccine Sales Value, 2020-2031
- 6.5.2 China Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- 6.5.3 China Peptide Cancer Vaccine Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Peptide Cancer Vaccine Sales Value, 2020-2031
- 6.6.2 Japan Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- 6.6.3 Japan Peptide Cancer Vaccine Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Peptide Cancer Vaccine Sales Value, 2020-2031
- 6.7.2 South Korea Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- 6.7.3 South Korea Peptide Cancer Vaccine Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Peptide Cancer Vaccine Sales Value, 2020-2031
- 6.8.2 Southeast Asia Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- 6.8.3 Southeast Asia Peptide Cancer Vaccine Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Peptide Cancer Vaccine Sales Value, 2020-2031
- 6.9.2 India Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- 6.9.3 India Peptide Cancer Vaccine Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 Boston Biomedical
- 7.1.1 Boston Biomedical Profile
- 7.1.2 Boston Biomedical Main Business
- 7.1.3 Boston Biomedical Peptide Cancer Vaccine Products, Services and Solutions
- 7.1.4 Boston Biomedical Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.1.5 Boston Biomedical Recent Developments
- 7.2 Ultimovacs
- 7.2.1 Ultimovacs Profile
- 7.2.2 Ultimovacs Main Business
- 7.2.3 Ultimovacs Peptide Cancer Vaccine Products, Services and Solutions
- 7.2.4 Ultimovacs Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.2.5 Ultimovacs Recent Developments
- 7.3 BrightPath Biotherapeutics
- 7.3.1 BrightPath Biotherapeutics Profile
- 7.3.2 BrightPath Biotherapeutics Main Business
- 7.3.3 BrightPath Biotherapeutics Peptide Cancer Vaccine Products, Services and Solutions
- 7.3.4 BrightPath Biotherapeutics Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.3.5 BrightPath Biotherapeutics Recent Developments
- 7.4 TapImmune
- 7.4.1 TapImmune Profile
- 7.4.2 TapImmune Main Business
- 7.4.3 TapImmune Peptide Cancer Vaccine Products, Services and Solutions
- 7.4.4 TapImmune Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.4.5 TapImmune Recent Developments
- 7.5 Immatics
- 7.5.1 Immatics Profile
- 7.5.2 Immatics Main Business
- 7.5.3 Immatics Peptide Cancer Vaccine Products, Services and Solutions
- 7.5.4 Immatics Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.5.5 Immatics Recent Developments
- 7.6 Sellas
- 7.6.1 Sellas Profile
- 7.6.2 Sellas Main Business
- 7.6.3 Sellas Peptide Cancer Vaccine Products, Services and Solutions
- 7.6.4 Sellas Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.6.5 Sellas Recent Developments
- 7.7 Imugene
- 7.7.1 Imugene Profile
- 7.7.2 Imugene Main Business
- 7.7.3 Imugene Peptide Cancer Vaccine Products, Services and Solutions
- 7.7.4 Imugene Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.7.5 Imugene Recent Developments
- 7.8 VAXON Biotech
- 7.8.1 VAXON Biotech Profile
- 7.8.2 VAXON Biotech Main Business
- 7.8.3 VAXON Biotech Peptide Cancer Vaccine Products, Services and Solutions
- 7.8.4 VAXON Biotech Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.8.5 VAXON Biotech Recent Developments
- 7.9 Generex Biotechnology
- 7.9.1 Generex Biotechnology Profile
- 7.9.2 Generex Biotechnology Main Business
- 7.9.3 Generex Biotechnology Peptide Cancer Vaccine Products, Services and Solutions
- 7.9.4 Generex Biotechnology Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.9.5 Generex Biotechnology Recent Developments
- 7.10 ISA Pharmaceuticals
- 7.10.1 ISA Pharmaceuticals Profile
- 7.10.2 ISA Pharmaceuticals Main Business
- 7.10.3 ISA Pharmaceuticals Peptide Cancer Vaccine Products, Services and Solutions
- 7.10.4 ISA Pharmaceuticals Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.10.5 ISA Pharmaceuticals Recent Developments
- 7.11 OncoTherapy Science
- 7.11.1 OncoTherapy Science Profile
- 7.11.2 OncoTherapy Science Main Business
- 7.11.3 OncoTherapy Science Peptide Cancer Vaccine Products, Services and Solutions
- 7.11.4 OncoTherapy Science Peptide Cancer Vaccine Revenue (US$ Million) & (2020-2025)
- 7.11.5 OncoTherapy Science Recent Developments
8 Industry Chain Analysis
- 8.1 Peptide Cancer Vaccine Industrial Chain
- 8.2 Peptide Cancer Vaccine Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Peptide Cancer Vaccine Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Peptide Cancer Vaccine Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
List of Tables
- Table 1. Peptide Cancer Vaccine Market Trends
- Table 2. Peptide Cancer Vaccine Market Drivers & Opportunity
- Table 3. Peptide Cancer Vaccine Market Challenges
- Table 4. Peptide Cancer Vaccine Market Restraints
- Table 5. Global Peptide Cancer Vaccine Revenue by Company (2020-2025) & (US$ Million)
- Table 6. Global Peptide Cancer Vaccine Revenue Market Share by Company (2020-2025)
- Table 7. Key Companies Peptide Cancer Vaccine Manufacturing Base Distribution and Headquarters
- Table 8. Key Companies Peptide Cancer Vaccine Product Type
- Table 9. Key Companies Time to Begin Mass Production of Peptide Cancer Vaccine
- Table 10. Global Peptide Cancer Vaccine Companies Market Concentration Ratio (CR5 and HHI)
- Table 11. Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Cancer Vaccine as of 2024)
- Table 12. Mergers & Acquisitions, Expansion Plans
- Table 13. Global Peptide Cancer Vaccine Sales Value by Pipeline: 2020 VS 2024 VS 2031 (US$ Million)
- Table 14. Global Peptide Cancer Vaccine Sales Value by Pipeline (2020-2025) & (US$ Million)
- Table 15. Global Peptide Cancer Vaccine Sales Value by Pipeline (2026-2031) & (US$ Million)
- Table 16. Global Peptide Cancer Vaccine Sales Market Share in Value by Pipeline (2020-2025)
- Table 17. Global Peptide Cancer Vaccine Sales Market Share in Value by Pipeline (2026-2031)
- Table 18. Global Peptide Cancer Vaccine Sales Value by Application: 2020 VS 2024 VS 2031 (US$ Million)
- Table 19. Global Peptide Cancer Vaccine Sales Value by Application (2020-2025) & (US$ Million)
- Table 20. Global Peptide Cancer Vaccine Sales Value by Application (2026-2031) & (US$ Million)
- Table 21. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2020-2025)
- Table 22. Global Peptide Cancer Vaccine Sales Market Share in Value by Application (2026-2031)
- Table 23. Global Peptide Cancer Vaccine Sales Value by Region, (2020 VS 2024 VS 2031) & (US$ Million)
- Table 24. Global Peptide Cancer Vaccine Sales Value by Region (2020-2025) & (US$ Million)
- Table 25. Global Peptide Cancer Vaccine Sales Value by Region (2026-2031) & (US$ Million)
- Table 26. Global Peptide Cancer Vaccine Sales Value by Region (2020-2025) & (%)
- Table 27. Global Peptide Cancer Vaccine Sales Value by Region (2026-2031) & (%)
- Table 28. Key Countries/Regions Peptide Cancer Vaccine Sales Value Growth Trends, (US$ Million): 2020 VS 2024 VS 2031
- Table 29. Key Countries/Regions Peptide Cancer Vaccine Sales Value, (2020-2025) & (US$ Million)
- Table 30. Key Countries/Regions Peptide Cancer Vaccine Sales Value, (2026-2031) & (US$ Million)
- Table 31. Boston Biomedical Basic Information List
- Table 32. Boston Biomedical Description and Business Overview
- Table 33. Boston Biomedical Peptide Cancer Vaccine Products, Services and Solutions
- Table 34. Revenue (US$ Million) in Peptide Cancer Vaccine Business of Boston Biomedical (2020-2025)
- Table 35. Boston Biomedical Recent Developments
- Table 36. Ultimovacs Basic Information List
- Table 37. Ultimovacs Description and Business Overview
- Table 38. Ultimovacs Peptide Cancer Vaccine Products, Services and Solutions
- Table 39. Revenue (US$ Million) in Peptide Cancer Vaccine Business of Ultimovacs (2020-2025)
- Table 40. Ultimovacs Recent Developments
- Table 41. BrightPath Biotherapeutics Basic Information List
- Table 42. BrightPath Biotherapeutics Description and Business Overview
- Table 43. BrightPath Biotherapeutics Peptide Cancer Vaccine Products, Services and Solutions
- Table 44. Revenue (US$ Million) in Peptide Cancer Vaccine Business of BrightPath Biotherapeutics (2020-2025)
- Table 45. BrightPath Biotherapeutics Recent Developments
- Table 46. TapImmune Basic Information List
- Table 47. TapImmune Description and Business Overview
- Table 48. TapImmune Peptide Cancer Vaccine Products, Services and Solutions
- Table 49. Revenue (US$ Million) in Peptide Cancer Vaccine Business of TapImmune (2020-2025)
- Table 50. TapImmune Recent Developments
- Table 51. Immatics Basic Information List
- Table 52. Immatics Description and Business Overview
- Table 53. Immatics Peptide Cancer Vaccine Products, Services and Solutions
- Table 54. Revenue (US$ Million) in Peptide Cancer Vaccine Business of Immatics (2020-2025)
- Table 55. Immatics Recent Developments
- Table 56. Sellas Basic Information List
- Table 57. Sellas Description and Business Overview
- Table 58. Sellas Peptide Cancer Vaccine Products, Services and Solutions
- Table 59. Revenue (US$ Million) in Peptide Cancer Vaccine Business of Sellas (2020-2025)
- Table 60. Sellas Recent Developments
- Table 61. Imugene Basic Information List
- Table 62. Imugene Description and Business Overview
- Table 63. Imugene Peptide Cancer Vaccine Products, Services and Solutions
- Table 64. Revenue (US$ Million) in Peptide Cancer Vaccine Business of Imugene (2020-2025)
- Table 65. Imugene Recent Developments
- Table 66. VAXON Biotech Basic Information List
- Table 67. VAXON Biotech Description and Business Overview
- Table 68. VAXON Biotech Peptide Cancer Vaccine Products, Services and Solutions
- Table 69. Revenue (US$ Million) in Peptide Cancer Vaccine Business of VAXON Biotech (2020-2025)
- Table 70. VAXON Biotech Recent Developments
- Table 71. Generex Biotechnology Basic Information List
- Table 72. Generex Biotechnology Description and Business Overview
- Table 73. Generex Biotechnology Peptide Cancer Vaccine Products, Services and Solutions
- Table 74. Revenue (US$ Million) in Peptide Cancer Vaccine Business of Generex Biotechnology (2020-2025)
- Table 75. Generex Biotechnology Recent Developments
- Table 76. ISA Pharmaceuticals Basic Information List
- Table 77. ISA Pharmaceuticals Description and Business Overview
- Table 78. ISA Pharmaceuticals Peptide Cancer Vaccine Products, Services and Solutions
- Table 79. Revenue (US$ Million) in Peptide Cancer Vaccine Business of ISA Pharmaceuticals (2020-2025)
- Table 80. ISA Pharmaceuticals Recent Developments
- Table 81. OncoTherapy Science Basic Information List
- Table 82. OncoTherapy Science Description and Business Overview
- Table 83. OncoTherapy Science Peptide Cancer Vaccine Products, Services and Solutions
- Table 84. Revenue (US$ Million) in Peptide Cancer Vaccine Business of OncoTherapy Science (2020-2025)
- Table 85. OncoTherapy Science Recent Developments
- Table 86. Key Raw Materials Lists
- Table 87. Raw Materials Key Suppliers Lists
- Table 88. Peptide Cancer Vaccine Downstream Customers
- Table 89. Peptide Cancer Vaccine Distributors List
- Table 90. Research Programs/Design for This Report
- Table 91. Key Data Information from Secondary Sources
- Table 92. Key Data Information from Primary Sources
List of Figures
- Figure 1. Peptide Cancer Vaccine Product Picture
- Figure 2. Global Peptide Cancer Vaccine Sales Value, 2020 VS 2024 VS 2031 (US$ Million)
- Figure 3. Global Peptide Cancer Vaccine Sales Value (2020-2031) & (US$ Million)
- Figure 4. Peptide Cancer Vaccine Report Years Considered
- Figure 5. Global Peptide Cancer Vaccine Players Revenue Ranking (2024) & (US$ Million)
- Figure 6. The 5 and 10 Largest Companies in the World: Market Share by Peptide Cancer Vaccine Revenue in 2024
- Figure 7. Peptide Cancer Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
- Figure 8. ITK-1 Picture
- Figure 9. GRN-1201 Picture
- Figure 10. TPIV200 Picture
- Figure 11. TPIV110 Picture
- Figure 12. UV1 Picture
- Figure 13. Galinpepimut-S Picture
- Figure 14. TARP 27-35 Picture
- Figure 15. HER-Vaxx Picture
- Figure 16. Vx-001 Picture
- Figure 17. Global Peptide Cancer Vaccine Sales Value by Pipeline (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 18. Global Peptide Cancer Vaccine Sales Value Market Share by Pipeline, 2024 & 2031
- Figure 19. Product Picture of Breast Cancer
- Figure 20. Product Picture of Lung Cancer
- Figure 21. Product Picture of Melanoma
- Figure 22. Product Picture of Prostate Cancer
- Figure 23. Product Picture of Others
- Figure 24. Global Peptide Cancer Vaccine Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million)
- Figure 25. Global Peptide Cancer Vaccine Sales Value Market Share by Application, 2024 & 2031
- Figure 26. North America Peptide Cancer Vaccine Sales Value (2020-2031) & (US$ Million)
- Figure 27. North America Peptide Cancer Vaccine Sales Value by Country (%), 2024 VS 2031
- Figure 28. Europe Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 29. Europe Peptide Cancer Vaccine Sales Value by Country (%), 2024 VS 2031
- Figure 30. Asia Pacific Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 31. Asia Pacific Peptide Cancer Vaccine Sales Value by Region (%), 2024 VS 2031
- Figure 32. South America Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 33. South America Peptide Cancer Vaccine Sales Value by Country (%), 2024 VS 2031
- Figure 34. Middle East & Africa Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 35. Middle East & Africa Peptide Cancer Vaccine Sales Value by Country (%), 2024 VS 2031
- Figure 36. Key Countries/Regions Peptide Cancer Vaccine Sales Value (%), (2020-2031)
- Figure 37. United States Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 38. United States Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- Figure 39. United States Peptide Cancer Vaccine Sales Value by Application (%), 2024 VS 2031
- Figure 40. Europe Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 41. Europe Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- Figure 42. Europe Peptide Cancer Vaccine Sales Value by Application (%), 2024 VS 2031
- Figure 43. China Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 44. China Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- Figure 45. China Peptide Cancer Vaccine Sales Value by Application (%), 2024 VS 2031
- Figure 46. Japan Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 47. Japan Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- Figure 48. Japan Peptide Cancer Vaccine Sales Value by Application (%), 2024 VS 2031
- Figure 49. South Korea Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 50. South Korea Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- Figure 51. South Korea Peptide Cancer Vaccine Sales Value by Application (%), 2024 VS 2031
- Figure 52. Southeast Asia Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 53. Southeast Asia Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- Figure 54. Southeast Asia Peptide Cancer Vaccine Sales Value by Application (%), 2024 VS 2031
- Figure 55. India Peptide Cancer Vaccine Sales Value, (2020-2031) & (US$ Million)
- Figure 56. India Peptide Cancer Vaccine Sales Value by Pipeline (%), 2024 VS 2031
- Figure 57. India Peptide Cancer Vaccine Sales Value by Application (%), 2024 VS 2031
- Figure 58. Peptide Cancer Vaccine Industrial Chain
- Figure 59. Peptide Cancer Vaccine Manufacturing Cost Structure
- Figure 60. Channels of Distribution (Direct Sales, and Distribution)
- Figure 61. Bottom-up and Top-down Approaches for This Report
- Figure 62. Data Triangulation
- Figure 63. Key Executives Interviewed
